This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Steer Clear of AmerisourceBergen Now (Revised)
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.
HRC vs. ABAX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. ABAX: Which Stock Is the Better Value Option?
Is Abaxis (ABAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABAX) Outperforming Other Medical Stocks This Year?
Is Abaxis (ABAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABAX) Outperforming Other Medical Stocks This Year?
Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle
by Zacks Equity Research
With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.
Zoetis (ZTS) Tides Over HSR Hurdle for Abaxis Acquisition
by Zacks Equity Research
Zoetis' (ZTS) waiting period under the HSR Act ends. It is related to its proposed merger with Abaxis for a purchase consideration of roughly $2 billion in aggregate.
Top Ranked Momentum Stocks to Buy for July 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 9th:
Here's Why You Should Add Abaxis (ABAX) to Your Portfolio
by Zacks Equity Research
We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.
Cardiovascular Systems (CSII) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Cardiovascular Systems (CSII) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High
by Zacks Equity Research
Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.
Company News For May 17, 2018
by Zacks Equity Research
Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
by Zacks Equity Research
Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.
Zacks.com highlights: Abaxis, Haynes International and Vectrus
by Zacks Equity Research
Zacks.com highlights: Abaxis, Haynes International and Vectrus
Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up
by Zacks Equity Research
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
3 of the Best Stocks to Buy for Solid Earnings Acceleration
by Tirthankar Chakraborty
If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be referred to as earnings acceleration.
LabCorp (LH) Beats on Q1 Earnings, Revenues, Lifts '18 View
by Zacks Equity Research
LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.
Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.
Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q1.
Quest Diagnostics (DGX) Q1 Earnings Meet, Guidance Intact
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q1 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
by Zacks Equity Research
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
Here's Why You Should Steer Clear of AmerisourceBergen Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.